ACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $263.07 million for the quarter. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. The business had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a net margin of 22.97% and a return on equity of 17.46%. The business's revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. On average, analysts expect ACADIA Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Up 4.0%

Shares of ACAD stock traded up $0.90 on Wednesday, reaching $23.53. 1,840,143 shares of the stock were exchanged, compared to its average volume of 1,611,068. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23. The firm has a 50 day moving average of $22.10 and a two-hundred day moving average of $18.95. The stock has a market cap of $3.94 billion, a P/E ratio of 17.18, a price-to-earnings-growth ratio of 4.93 and a beta of 0.64.

Insider Activity

In related news, insider James Kihara sold 4,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the sale, the insider owned 20,395 shares in the company, valued at $458,887.50. This represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 2,000 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the transaction, the executive vice president owned 62,130 shares of the company's stock, valued at $1,553,250. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,271 shares of company stock valued at $525,079 over the last quarter. Corporate insiders own 26.50% of the company's stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACAD. Royal Bank of Canada raised its holdings in ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company's stock valued at $1,338,000 after acquiring an additional 34,352 shares in the last quarter. AQR Capital Management LLC grew its stake in ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company's stock valued at $1,124,000 after acquiring an additional 2,492 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in ACADIA Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company's stock valued at $1,498,000 after acquiring an additional 6,303 shares in the last quarter. Empowered Funds LLC acquired a new stake in ACADIA Pharmaceuticals in the 1st quarter valued at $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ACADIA Pharmaceuticals by 14.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company's stock valued at $4,170,000 after acquiring an additional 31,931 shares during the period. Hedge funds and other institutional investors own 96.71% of the company's stock.

Wall Street Analysts Forecast Growth

ACAD has been the topic of several analyst reports. Mizuho raised their target price on ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a "neutral" rating in a research report on Monday, May 19th. Royal Bank Of Canada upped their price objective on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 and gave the stock an "outperform" rating in a report on Monday, June 23rd. Cantor Fitzgerald upgraded shares of ACADIA Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Robert W. Baird boosted their price target on shares of ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Monday, May 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $28.13.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.